Home / Market News / $ACRS

$ACRS news and market catalysts

The 11 most recent market catalysts affecting $ACRS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

11 catalysts 2 high impact 3 bullish 4 bearish Biotechnology
Nov 18, 2026 Corporate Catalyst Bearish Impact 75
Wedbush Downgrades Aclaris Therapeutics to Neutral
Wedbush downgraded Aclaris Therapeutics (ACRS) from Outperform to Neutral and slashed its price target from $8 to $3. This significant revision reflects a more cautious outlook fro…
Nov 16, 2026 Corporate Catalyst Bearish Impact 95
Aclaris Therapeutics Announces Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug
Aclaris Therapeutics reported that its Phase 2 ADMIRATION trial for bosakitug, a potential treatment for moderate-to-severe atopic dermatitis, did not achieve its primary endpoint.…
Nov 5, 2026 Corporate Catalyst Neutral Impact 85
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics announced positive primary analysis results from its Phase 1b trials for ATI-052 in atopic dermatitis and asthma, which are crucial early-stage indicators of d…
Oct 31, 2026 Corporate Catalyst Bullish Impact 65
Canaccord Genuity Raises Price Target for Aclaris Therapeutics
Canaccord Genuity, an analyst firm, reaffirmed its 'Buy' rating for Aclaris Therapeutics (ACRS) and raised its price target from $10 to $13. This 30% increase in the price target s…
Oct 29, 2026 Corporate Catalyst Bearish Impact 55
Wedbush Adjusts Aclaris Therapeutics Price Target to $8
Wedbush Securities has adjusted its price target for Aclaris Therapeutics (ACRS) from $10 to $8. This action is significant because a price target reduction typically signals a mor…
Oct 27, 2026 Corporate Catalyst Neutral Impact 65
Aclaris Therapeutics Prices $50 Million Public Offering
Aclaris Therapeutics priced a public offering of common stock and pre-funded warrants, expecting to generate $50 million in gross proceeds. This capital raise, while providing esse…
Oct 27, 2026 Corporate Catalyst Bullish Impact 75
Aclaris Therapeutics Reports Positive Phase 1b Proof-of-Concept Results for ATI-052
Aclaris Therapeutics reported positive Phase 1b proof-of-concept results for ATI-052, its anti-TSLP/IL-4Rα bispecific candidate, in atopic dermatitis and asthma. The rapid improvem…
Oct 27, 2026 Corporate Catalyst Neutral Impact 65
Piper Sandler Acts as Joint Bookrunning Manager for Aclaris Therapeutics Offering
Aclaris Therapeutics is undertaking a capital raise through an offering of common stock and pre-funded warrants. This is significant because it signals the company's need for addit…
Sep 1, 2026 Corporate Catalyst Neutral Impact 65
Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10
Canaccord Genuity's initiation of coverage on Aclaris Therapeutics with a 'Buy' rating and a $10 price target is a positive development for the company. Analyst coverage can increa…
Aug 6, 2026 Corporate Catalyst Bullish Impact 75
Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026
The FDA Fast Track designation for Modzatinib is a significant positive catalyst for Aclaris Therapeutics (ACRS). It signals regulatory confidence in the drug's potential and will …
Aug 6, 2026 Corporate Catalyst Bearish Impact 75
Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate
Aclaris Therapeutics (ACRS) announced its Q2 earnings, reporting a loss of $(0.15) per share and sales of $1.629 million. Both figures surpassed analyst consensus estimates, which …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.